Research Article
Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients
Table 4
characterization of type 2 diabetes with NAFLD, grouped by metformin usage.
| Characteristics | Not-used metformin () | Used metformin () | /2/ value | value |
| General | | | | | Male (, %) | 44 (66.67%) | 51 (64.56%) | 0.071 | 0.790 | Age (years) | | | 0.784 | 0.434 | BMI (kg/m2) | | | 3.903 | <0.001 | BMR (%) | | | 0.472 | 0.637 | Duration of diabetes (y) | 5 (2, 9) | 6 (2, 10.5) | 0.872 | 0.513 | Use of hypoglycemic drugs | | | | | Insulin (, %) | 17 (25.76%) | 21 (26.58%) | 0.013 | 0.910 | (, %) | 10 (15.15%) | 8 (10.13%) | 0.835 | 0.361 | (, %) | 34 (51.52%) | 31 (39.24%) | 2.191 | 0.139 | (, %) | 15 (22.73%) | 12 (15.19%) | 1.348 | 0.246 | (, %) | 36 (54.55%) | 35 (44.30%) | 1.509 | 0.219 | Biochemical data | | | | | ALT (IU/L) | 22 (14, 35) | 25.5 (16, 41) | -1.681 | 0.134 | HOMA-IR | 3.59 (1.62, 6.61) | 3.20 (1.36, 5.48) | 2.092 | 0.011 | eGFR (mL/min/1.73 m2) | | | 1.887 | 0.061 | HbA1c (%) | | | 0.555 | 0.580 | Thyroid metabolism | | | | | FT3 (pmol/L) | | | 2.064 | 0.041 | FT4 (pmol/L) | | | 1.613 | 0.109 | FT3/FT4 ratio | | | 0.8219 | 0.413 | TSH (mIU/L) | | | 1.978 | 0.049 |
|
|
Data are (%), , or median (interquartile range). BMI: body mass index; BMR: basal metabolic rate; ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model assessment-insulin resistance; DPP-4i: dipeptidyl peptidase 4 inhibitors; FT3: free triiodothyronine; TSH: thyroid stimulating hormone; FT4: free thyroxine; NAFLD: nonalcoholic fatty liver disease. |